Yamada Shin-Ichi, Kurita Hiroshi, Kamata Takahiro, Kirita Tadaaki, Ueda Michihiro, Yamashita Tetsuro, Ota Yoshihide, Otsuru Mitsunobu, Yamakawa Nobuhiro, Okura Masaya, Aikawa Tomonao, Umeda Masahiro
Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Department of Oral and Maxillofacial Surgery, School of Medicine, Nara Medical University, 840 Shijo-Cho, Kashihara, 634-8521, Japan.
Odontology. 2018 Jan;106(1):96-102. doi: 10.1007/s10266-017-0318-1. Epub 2017 Sep 21.
The purpose of this study was to investigate the prognostic factor in salivary gland carcinoma patients. Clinical and pathological data of 211 consecutive patients who treated with curative intent were analyzed. The overall survival (OS) rate, local control rate, and distant metastasis rate were calculated. To examine a prognostic factor in salivary gland carcinoma patients, a multivariate analysis was performed. The 5-year-OS rate was 84.0%, and 10-year was 69.2%. The 5-year-local control rate was 84.6%, and 10-year was 70.1%. The 5-year-distant metastasis rate was 16.9%, and 10-year was 21.1%. In a multivariate analysis, the OS rate was affected by pN(+), high-grade malignancy, and primary tumor size. The local control was affected by the primary tumor size, high-grade malignancy, and the status of the surgical margin. The primary tumor size and pN(+) were associated with the distant metastasis. The results of this study suggested that pN(+), malignancy grade, primary tumor size, and the margin status might affect the prognosis of salivary gland carcinoma patients. Postoperative radiotherapy and adjuvant chemotherapy were suggested the possibility of contribution to the good prognosis of salivary gland carcinoma patients.
本研究的目的是调查涎腺癌患者的预后因素。对211例接受根治性治疗的连续患者的临床和病理数据进行了分析。计算了总生存率（OS）、局部控制率和远处转移率。为了研究涎腺癌患者的预后因素，进行了多因素分析。5年总生存率为84.0%，10年为69.2%。5年局部控制率为84.6%，10年为70.1%。5年远处转移率为16.9%，10年为21.1%。在多因素分析中，总生存率受pN(+)、高级别恶性肿瘤和原发肿瘤大小影响。局部控制受原发肿瘤大小、高级别恶性肿瘤和手术切缘状态影响。原发肿瘤大小和pN(+)与远处转移有关。本研究结果表明，pN(+)、恶性程度分级、原发肿瘤大小和切缘状态可能影响涎腺癌患者的预后。术后放疗和辅助化疗提示可能有助于涎腺癌患者的良好预后。
